Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction

Bersani, F. Saverio ; Mellon, Synthia H. ; Lindqvist, Daniel LU ; Kang, Jee In ; Rampersaud, Ryan ; Somvanshi, Pramod Rajaram ; Doyle, Francis J. ; Hammamieh, Rasha ; Jett, Marti and Yehuda, Rachel , et al. (2020) In Military medicine 185(1). p.311-318
Abstract

INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism,... (More)

INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism, inflammation, mitochondrial function, and perhaps the gut microbiome in PTSD. Several inadequately tested targets of pharmacological intervention are proposed, including insulin sensitizers, lipid regulators, anti-inflammatories, and mitochondrial biogenesis modulators. CONCLUSIONS: Systemic pathologies that are intricately involved in brain functioning and behavior may not only contribute to somatic comorbidities in PTSD, but may represent novel targets for treating core psychiatric symptoms.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Military medicine
volume
185
issue
1
pages
8 pages
publisher
Association of Military Surgeons of the US
external identifiers
  • scopus:85079756639
  • pmid:32074311
ISSN
1930-613X
DOI
10.1093/milmed/usz260
language
English
LU publication?
yes
id
dfd7586f-8723-4686-999c-61d5bda4df79
date added to LUP
2020-03-18 13:32:39
date last changed
2024-06-26 12:01:40
@article{dfd7586f-8723-4686-999c-61d5bda4df79,
  abstract     = {{<p>INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism, inflammation, mitochondrial function, and perhaps the gut microbiome in PTSD. Several inadequately tested targets of pharmacological intervention are proposed, including insulin sensitizers, lipid regulators, anti-inflammatories, and mitochondrial biogenesis modulators. CONCLUSIONS: Systemic pathologies that are intricately involved in brain functioning and behavior may not only contribute to somatic comorbidities in PTSD, but may represent novel targets for treating core psychiatric symptoms.</p>}},
  author       = {{Bersani, F. Saverio and Mellon, Synthia H. and Lindqvist, Daniel and Kang, Jee In and Rampersaud, Ryan and Somvanshi, Pramod Rajaram and Doyle, Francis J. and Hammamieh, Rasha and Jett, Marti and Yehuda, Rachel and Marmar, Charles R. and Wolkowitz, Owen M.}},
  issn         = {{1930-613X}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{311--318}},
  publisher    = {{Association of Military Surgeons of the US}},
  series       = {{Military medicine}},
  title        = {{Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction}},
  url          = {{http://dx.doi.org/10.1093/milmed/usz260}},
  doi          = {{10.1093/milmed/usz260}},
  volume       = {{185}},
  year         = {{2020}},
}